Table 3. PVI and FCV of PDGFR-α and PDGFR-β as prognostic factors for overall survival in multivariate analyses in patients with mCRC (SPCRC cohort).
| Adjusted with PDGFR-α n=278 | Adjusted with PDGFR-β n=307 | |||||||
|---|---|---|---|---|---|---|---|---|
| PVI | FCV | PVI | FCV | |||||
| variable | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value |
| PDGFR-α (low vs. high) | 1.31 (0.01-1.70) |
0.045 | 1.30 (1.00-1.68) |
0.043 | - | - | - | - |
| PDGFR-β (low vs. high) | - | - | - | - | 1.51 (1.18-1.94) |
0.001 | 1.44 (1.12-1.84) |
0.004 |
| Alkaline Phosphatase (elevated vs. normal) | 1.63 (1.26-2.10) |
0.001 | 1.63 (1.26-2.11) |
<0.001 | 1.62 (1.26-2.08) |
<0.001 | 1.61 (1.25-2.06) |
<0.001 |
| Performance status (1, 2 vs. 0) | 1.45 (1.10-1.91) |
0.008 | 1.48 (1.12-1.94) |
0.005 | 1.47 (1.13-1.92) |
0.004 | 1.48 (1.14-1.92) |
0.004 |
| Performance status (3, 4 vs. 0) | 6.78 (4.44-10.35) |
<0.001 | 6.76 (4.43-10.33) |
<0.001 | 7.44 (5.01-11.03) |
<0.001 | 7.43 (5.01-11.03) |
<0.001 |
| BRAF (mut vs. wt) | 2.08 (1.46-2.94) |
<0.001 | 2.13 (1.51-3.01) |
<0.001 | 2.19 (1.59-3.01) |
<0.001 | 2.21 (1.61-3.05) |
<0.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; mut, mutant; wt, wild type.